This press conference on "Treatment and Resistance to Targeted Therapies,” held Sunday, April 7, was hosted by Levi Garraway, M.D., Ph.D., assistant professor of medicine in the department of medical oncology at the Dana-Farber Cancer Institute, and featured the following research:
Listen to a recording of the teleconference:
- Intermittent Treatment With Vemurafenib May Prevent Lethal Drug Resistance in Melanoma
- Novel Drug Combination Showed Antitumor Activity in Patients With Incurable BRCA-deficient Cancers
- AKT Inhibitor AZD5363 Well Tolerated Yielded Partial Response in Patients With Advanced Solid Tumors
- Preclinical Study Indicates Potential for Novel Inhibitor to Overcome Drug Resistance Induced by RAF MEK Inhibitors
Listen to the teleconference or download* the mp3 of the teleconference (9.23 MB, 40 minutes and 15 seconds)
*On a PC, right mouse click on the "download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.